Crescita Therapeutics, Inc. CRRTF
0.56 USD 0.00 (+0.00%)
At closeJun 4, 2026, 4:00 PM EDT
0.5519 Day range 0.5587
0.021 52-week range 0.57305
- YTD
- +62.46%
- 1 year
- +43.22%
News
globenewswire.com Knight Announces Early Warning Filing Regarding Shares of Crescita MONTREAL, June 05, 2026 (GLOBE NEWSWIRE) -- This press release is disseminated by Knight Therapeutics Inc. ("Knight") (TSX:GUD), a pan-American (ex-US) pharmaceutical company, as required by…
businesswire.com Crescita Therapeutics Inc. Announces Closing of Arrangement LAVAL, Québec--(BUSINESS WIRE)--Crescita Therapeutics Inc. (TSX: CTX and OTC US: CRRTF) (“Crescita” or the “Company”) is pleased to announce the closing of the previously announced plan of…
businesswire.com Crescita Therapeutics Inc. Announces Final Consideration Payable to Shareholders Pursuant to Arrangement with ClinActiv LAVAL, Québec--(BUSINESS WIRE)--Crescita Therapeutics Inc. (TSX: CTX and OTC US: CRRTF) (“Crescita” or the “Company”) is pleased to announce that holders of the issued and outstanding common shares…
businesswire.com Crescita Therapeutics Inc. Obtains Final Order Approving Plan of Arrangement LAVAL, Québec--(BUSINESS WIRE)--Crescita Therapeutics Inc. (TSX: CTX and OTC US: CRRTF) (“Crescita” or the “Company”) is pleased to announce that it has obtained a final court order from the Ontario…
businesswire.com Crescita Obtains Shareholder Approval To Be Acquired By ClinActiv Holdings LAVAL, Québec--(BUSINESS WIRE)--Crescita Therapeutics Inc. (TSX: CTX and OTC US: CRRTF) (“Crescita” or the “Company”) today announced that at its special meeting (the “Meeting”) of shareholders (the…
businesswire.com Crescita Reports First Quarter 2026 Results LAVAL, Québec--(BUSINESS WIRE)--Crescita Therapeutics Inc. (TSX: CTX and OTC US: CRRTF) (“Crescita” or the “Company”), a growth-oriented, innovation-driven Canadian commercial dermatology company,…
businesswire.com Crescita Announces Filing and Mailing of Special Meeting Materials and Receipt of Interim Order in respect of Arrangement with ClinActiv Holdings LAVAL, Quebec--(BUSINESS WIRE)--Crescita Therapeutics Inc. (TSX: CTX and OTC US: CRRTF) (“Crescita” or the “Company”) announced today that it has filed and mailed the management information circular…
businesswire.com Crescita Reports Q4 and Fiscal 2025 Results LAVAL, Québec--(BUSINESS WIRE)--Crescita Therapeutics Inc. (TSX: CTX and OTC US: CRRTF) (“Crescita” or the “Company”), a growth-oriented, innovation-driven Canadian commercial dermatology company,…
businesswire.com Crescita Announces Definitive Agreement to Be Acquired by ClinActiv Holdings in an All-Cash Transaction at a Significant Premium LAVAL, Quebec--(BUSINESS WIRE)--Crescita Therapeutics Inc. (TSX: CTX and OTC US: CRRTF) (“Crescita” or the “Company”) today announced that it has entered into a definitive arrangement agreement (the…
businesswire.com Crescita Reports Third Quarter 2025 Results LAVAL, Quebec--(BUSINESS WIRE)--Crescita Therapeutics Inc. (TSX: CTX and OTC US: CRRTF) (“Crescita” or the “Company”), a growth-oriented, innovation-driven Canadian commercial dermatology company,…
businesswire.com Crescita Therapeutics Announces the Results of its Annual General and Special Meeting of Shareholders LAVAL, Quebec--(BUSINESS WIRE)--Crescita Therapeutics Inc. (TSX: CTX and OTC US: CRRTF) (“Crescita” or the “Company”), a growth-oriented, innovation-driven Canadian commercial dermatology company,…
businesswire.com Crescita Therapeutics Announces Mutual Termination of Licensing Agreement with Croma Pharma GmbH for Pliaglis® LAVAL, Quebec--(BUSINESS WIRE)--Crescita Therapeutics Inc. (TSX: CTX and OTC US: CRRTF) (“Crescita” or the “Company”), a growth-oriented, innovation-driven Canadian commercial dermatology company…
businesswire.com Crescita Reports First Quarter 2025 Results LAVAL, Quebec--(BUSINESS WIRE)--Crescita Therapeutics Inc. (TSX: CTX and OTC US: CRRTF) (“Crescita” or the “Company”), a growth-oriented, innovation-driven Canadian commercial dermatology company,…
businesswire.com Crescita Reports Third Quarter 2024 Results LAVAL, Quebec--(BUSINESS WIRE)--Crescita Therapeutics Inc. (TSX: CTX and OTC US: CRRTF) (“Crescita” or the “Company”), a growth-oriented, innovation-driven Canadian commercial dermatology company,…
businesswire.com Crescita Therapeutics Announces Approval of Normal Course Issuer Bid LAVAL, Quebec--(BUSINESS WIRE)--Crescita Therapeutics Inc. (TSX: CTX and OTC US: CRRTF) (“Crescita” or the “Company”), a growth-oriented, innovation-driven Canadian commercial dermatology company,…
businesswire.com Crescita Reports Second Quarter 2024 Results LAVAL, Quebec--(BUSINESS WIRE)--Crescita Therapeutics Inc. (TSX: CTX and OTC US: CRRTF) (“Crescita” or the “Company”), a growth-oriented, innovation-driven Canadian commercial dermatology company,…
businesswire.com Leading Canadian Healthcare Services Provider Selects Crescita as Exclusive Manufacturing Partner under 5-Year Agreement LAVAL, Quebec--(BUSINESS WIRE)--Crescita Therapeutics Inc. (TSX: CTX and OTC US: CRRTF) (“Crescita” or the “Company”), a growth-oriented, innovation-driven Canadian commercial dermatology company…
businesswire.com Crescita Therapeutics Announces the Results of its Annual General and Special Meeting of Shareholders LAVAL, Quebec--(BUSINESS WIRE)--Crescita Therapeutics Inc. (TSX: CTX and OTC US: CRRTF) (“Crescita” or the “Company”), a growth-oriented, innovation-driven Canadian commercial dermatology company,…
businesswire.com Crescita Reports Q4 and Fiscal 2023 Results LAVAL, Quebec--(BUSINESS WIRE)--Crescita Therapeutics Inc. (TSX: CTX and OTC US: CRRTF) (“Crescita” or the “Company”), a growth-oriented, innovation-driven Canadian commercial dermatology company,…
businesswire.com Crescita Reports Third Quarter 2023 Results LAVAL, Québec--(BUSINESS WIRE)--Crescita Therapeutics Inc. (TSX: CTX and OTC US: CRRTF) (“Crescita” or the “Company”), a growth-oriented, innovation-driven Canadian commercial dermatology company,…